Bristol-Myers Squibb has posted net income of $852 million for the fourth quarter, up over 76%, and helped by lower taxes, while revenues climbed 7% to $5.45 billion driven by the strong performance of its antivirals.
The company's bloodthinner blockbuster Plavix (clopidogrel) slipped 3% to $1.67 billion, while sales of the antipsychotic Abilify (aripiprazole) rose 4% to $707 million. However, the antihypertensive Avapro/Avalide (irbesartan) was down 23% to $195 million.
As for the firm's HIV drugs, sales of the Sustiva (efavirenz) franchise rose 14% to $412 million, and Reyataz (atazanavir) was up 11% to $416 million. Revenues from Baraclude (entecavir) for hepatitis B climbed 20% to $318 million.
Sprycel (dasatanib) for leukaemia leapt 34% to $227 million, while Orencia (abatacept) for rheumatoid arthritis increased 27% to $257 million. The cancer agent Erbitux (cetuximab) was up 10% to $181 million, while the recently-launched melanoma drug Yervoy (ipilimumab) contributed $144 million. One of the most striking performances was that of Onglyza (saxagliptin) and the recently-launched Kombiglyze (saxagliptin/metformin), which together delivered $153 million in sales.
Chief executive Lamberto Andreotti said the quarter saw solid financial results, "concluding a very good year that sets the foundation for the long-term growth of the company". He added that in 2012, B-MS "will build on the momentum…as we transition beyond the loss of exclusivity of Plavix and Avapro”.
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.